Drug intelligence / Profile preview

palonosetron buccal film

Development stage: Unknown
Lead developer: LIPIN Pharmaceutical
Modality: Small Molecules
Administration: Buccal

Overview

Palonosetron buccal film is a novel formulation of the long-acting 5-HT3 receptor antagonist palonosetron hydrochloride, developed by Xiamen LP Pharmaceutical. It is specifically designed for the prevention of chemotherapy-induced nausea and vomiting (CINV) in cancer patients receiving moderately emetogenic chemotherapy (MEC). The drug utilizes a proprietary mucosal delivery platform to provide a non-invasive alternative to intravenous palonosetron. Palonosetron works by selectively and competitively antagonizing serotonin (5-HT3) receptors in both the peripheral and central nervous systems, thereby inhibiting the emetic reflex triggered by chemotherapeutic agents.

Other names: palonosetron HCl buccal filmpalonosetron hydrochloride buccal film

Targets

HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on palonosetron buccal film.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on palonosetron buccal film.